Abstract | A significant body of data implicates the type I interferon (IFN) pathway in the pathogenesis of autoimmune rheumatic diseases. In these disorders, a self-reinforcing cycle of IFN production can contribute to immunopathology through multiple mechanisms. Type I IFN cytokines are pleiotropic in their effects, mediating antiviral and antitumor activities, and possess numerous immunomodulatory functions for both the innate and adaptive immune responses. A key principle of the type I IFN system is rapid induction and amplification of the signaling pathway, which generates a feed-forward loop of IFN production, ensuring that a vigorous antiviral immune response is mounted. Although such feed-forward pathways are highly adaptive when it comes to rapid and effective virus eradication, this amplification can be maladaptive in immune responses directed against host tissues. Such feed-forward loops, however, create special opportunities for therapy.
Introduction
Systemic autoimmune diseases, which include systemic lupus erythematosus (SLE), myositis, Sjögren's syndrome (SS), systemic sclerosis (SSc) and rheumatoid arthritis (RA), are a complex group of heterogeneous disorders that are characterized by an antigen-driven immune response against self with the destruction of host tissue. A hallmark of these diseases is their self-sustaining and autoamplifying nature, in which immune-mediated tissue damage and tissue repair collaborate in a feed-forward loop to provide the destructive power and the fuel that sustain the process. In this regard, different modes of cell death and enhanced autoantigen expression in regenerating cells seem to have key roles. 1, 2 The disease phenotypes are quite distinct in terms of the primary tissues targeted, the specific auto antibodies elaborated, and the inflammatory and immune effector pathways that predominate. Despite the different nature of each disease, however, they clearly share some pathogenetic mechanisms.
Over the past three decades, a substantial body of data has accumulated that implicates type I interferons (IFNs) in the pathogenesis of systemic autoimmune diseases. Type I IFN cytokines are pleiotropic in their effects, mediating antiviral and antitumor activities, and possessing numerous immunomodulatory functions, with the capacity to amplify both innate and adaptive immune responses. Understanding which of these effects contributes to autoimmune disease pathogenesis, and whether these effects can be exploited therapeutically, remain important questions.
In this Review, we introduce evidence implicating the type I IFN pathway in the initiation and propagation of systemic autoimmune disease and examine the mechanisms that regulate type I IFN production. The selfamplifying features of this pathway and its relevance to autoimmunity are highlighted, and opportunities and potential pitfalls in therapeutically targeting type I IFNs are addressed.
The IFN family
IFNs were initially identified as secreted factors capable of inhibiting viral replication. Later studies, however, revealed three distinct classes of IFN, each capable of mediating a wide array of biological functions. The members of the IFN family-type I, type II and type III-are classified on the basis of structural ho mology and chromosomal localiza tion, and each type signals through a unique receptor complex (Table 1) . Type I IFNs (comprising IFN-α, IFN-β, IFN-ω, IFN-ε and IFN-κ) and type III IFN (IFN-λ) can be produced by almost all nucleated cells. They activate identical signaling pathways, induce an overlapping set of genes, and mediate potent antiviral effects. [3] [4] [5] [6] A major difference between type I and type III IFNs is that the former's receptor is ubi quitously expressed, rendering all cells capable of responding to type I IFNs, whereas the type III IFN receptor seems to have limited distribution (primarily on epithelial cells and plasmacytoid dendritic cells), 7, 8 which suggests that a limited array of cells respond to type III IFN.
Type II IFN (IFN-γ) is quite distinct from types I and III IFN. Only natural killer (NK) cells, NK T cells and T-cell populations produce IFN-γ, and signaling through the IFN-γ receptor activates some pathways that are shared with types I and III IFN, as well as some distinct pathways. 9 The primary role of IFN-γ is to modulate the adaptive immune response, 10 although it is also capable
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of mediating limited antiviral effects. Although all three classes of IFN can have a pathogenic role in auto immunity, this Review focuses on type I IFNs.
The roles of type I IFNs
The type I IFN system constitutes a family of cytokines that can be produced by all nucleated cells upon recognition of conserved viral and bacterial structures (Table 1) . [11] [12] [13] Interestingly, although the family members are largely similar, there are some nuances to the downstream effects of each type I IFN cytokine.
14 The considerable redundancy of the type I IFN genes is thought to signify the evolutionary importance of this pathway. In vivo observations in humans and mice underscore the critical role of type I IFNs in the antiviral response. many viruses encode inhibitors of type I IFN signaling and production, 15 which highlights the selective pressure that the IFN system places on viral success. In addition, human deficiencies in genes related to the IFN signaling pathway render individuals highly susceptible to various infections. For example, mutations in tyrosine kinase 2 (TYK2), a type I and type III IFN receptor-associated Janus kinase that is necessary for signal transduction through the IFN receptors, renders indivi duals suscep tible to viral, bacterial and fungal infections. 16 Deficiency in signal transducer and activator of transcription (STAT) 1, which is activated downstream of all IFN receptors and is critical for the induction of IFN-stimulated genes, results in early le thality from viral disease. 17 Studies in mice are consistent with these findings. mice deficient in the type I IFN receptor quickly succumb to sublethal challenge with a variety of viruses. 18, 19 In addition to its effects on viral infection, signaling through the type I IFN receptor prevents tumor growth, 20 probably via the activation of NK cells and cytolytic T cells. 21, 22 The role of type I IFNs in the antiviral and antitumor response is further highlighted by the clinical efficacy of IFN compounds in the treatment of chronic viral infections (such as hepatitis C) and some malignancies (such as hairy cell leukemia and melanoma).
Although type I IFNs are critical for the host immune response, several lines of evidence strongly suggest that these cytokines are directly involved in the patho genesis of systemic autoimmune disease. First, it is known that IFN immunotherapy can induce autoimmunity. Second, circulating immune complexes can initiate IFN production and dendritic cell (DC) maturation. Third, studies have shown a high level of IFN-regulated gene expression in patients with systemic autoimmunity. Finally, polymorphisms in IFN pathway genes are associ ated with an increased risk of systemic autoimmune disease.
Autoimmunity induced by IFN therapy
High-dose IFN therapy is effective in treating chronic viral disease and malignancy. In some patients, however, this treatment has been associated with the generation of autoimmunity. 23 The autoimmune phenomena that manifest are quite diverse, ranging from the induction of autoantibodies to the development of autoimmune di seases including SLE, polymyositis, and RA. Although
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Key points
The type I interferon (IFN) system constitutes a highly redundant group ■ of cytokines that are of critical importance to host survival IFN immunotherapy is directly related to the development of autoimmunity, the development of overt auto immune disease in these individuals is rare, which suggests that additional genetic and environmental susceptibility factors are necessary to induce disease. Interestingly, the autoimmune symptoms that manifest can resolve after the cessation of treatment, 24 suggesting that, although type I IFNs can initiate symptoms of autoimmunity, additional factors are required for the initiation of a self-propagating loop. These findings have implications for the treatment of autoimmune disease, whereby inhibiting the self-propagating cycle of tissue destruction and regeneration could stop disease flares.
Immune complexes and IFN production Elevated type I IFN levels in the serum of patients with systemic autoimmunity were described several decades ago, 25 but were largely ignored. momentum for a pathogenic role of type I IFNs was provided by Rönnblom and colleagues when they demonstrated that elevated serum IFN-α levels could be driven by immune complexes. 26, 27 In their study, when immunoglobulin from patients with SLE was combined with plasmid DNA or apoptotic cells and added to peripheral blood mononuclear cells (PBmCs), IFN was produced. Similar findings have been described in patients with SS and SSc. 28, 29 Subsequently, Blanco and colleagues 30 demon strated that serum from patients with SLE was capable of inducing the maturation of monocytes into DCs in an IFN-α-dependent manner.As prominent regulators of T-cell activation, DCs occupy a central position in the immune system. Chronic DC maturation in the presence of increased IFN levels might have a central role in autoimmunity by activating autoreactive T cells to drive the autoimmune destruction of target tissues. The capacity of self antigen-containing immune complexes to stimulate IFN production further contributes to a self-propagating loop of tissue damage.
expression of IFN-regulated genes
Studies from multiple groups have demonstrated increased expression of a subset of type I IFN-regulated genes in PBmCs from patients with SLE compared with those of healthy controls. [31] [32] [33] [34] Furthermore, expression of this socalled 'IFN signature' correlated with disease se verity and activity in a proportion of these patients. 31, 32, 35 Consistent with the fact that IFN immunotherapy can induce a multitude of autoimmune diseases, other studies have demonstrated that the IFN signature is expressed more RevIews commonly across the rheumatic syndromes than other autoimmune diseases. For example, PBmCs from patients with dermatomyositis, SS and SSc express a similar group of IFN-regulated genes at high levels. [36] [37] [38] [39] In addition, studies of tissue from patients with dermatomyositis or SS demonstrated that IFN-regulated genes and proteins are expressed at high levels in the relevant disease microenvironment. 40, 41 Professional type I IFN-producing plasma cytoid DCs (pDCs) are enriched in the inflamed muscle and salivary glands of patients with dermatomyositis and SS, respectively; 40, 41 this finding provides evidence for IFN expression in inflamed tissues. Of importance, despite a positive associ ation between increased IFN-regulated gene expression and disease activity and/or severity, the IFN signature is only expressed in a subset of patients with active disease, which suggests that other mechanisms contribute to disease pathogenesis. As viral infections can be difficult to distinguish from disease flares, further studies are necessary to determine how the different signatures observed in disease subsets differ from those observed during acute or chronic viral infection, or during IFN therapy.
gene polymorphisms of the IFN pathway Studies have identified polymorphisms within genes of the IFN pathway that confer an increased risk for several systemic autoimmune diseases. These genetic effects should be viewed as 'gain' switches, which influence the nature or magnitude of a response, rather than as binary switches, which turn a response either 'on' or 'off ' . Gain switches are particularly relevant in diseases where feed-forward loops contribute to pathogenesis.
Interferon regulatory factor (IRF5) 5 is a member of a family of transcription factors that regulate the production of type I IFNs (discussed below). The original description of an association between IRF5 and SLE 42 has been widely replicated, and several single nucleotide polymorphisms have been identified that regulate both splicing and expression of IRF5. 43, 44 Furthermore, the risk haplotype of IRF5 is associated with increased serum IFN-α activity in patients with SLE. 45 However, the presence of this haplotype is clearly not the only mechanism regulating the IFN response, as anti-RNA binding protein and/or anti-double-stranded DNA antibodies in these individuals can also predict increased serum IFN-α activity. 45 In addition, studies have suggested that IRF5 polymorphisms are associated with an increased risk of SS and SSc. 46, 47 STAT4 is activated downstream of a number of cytokines, including type I IFNs, and contributes to T-cell differen tiation and IFN-γ production. 48, 49 Polymorphisms within STAT4 have been linked with an increased risk of RA and SLE. 50 Patients with SLE and the STAT4 risk haplo type have a more severe disease phenotype, and seem to have increased sensitivity to type I IFNs, than patients lacking this haplotype. 52, 52 The functional significance of these polymorphisms on activation of the type I IFN pathway requires further attention.
Self-amplifying IFN production
The self-amplifying nature of autoimmune diseases has an interesting counterpart in the type I IFN system, which is characterized by its striking capacity to amplify rapidly. many of the receptors, signal transduction molecules and transcription factors that drive IFN production are themselves regulated by IFNs. 53, 54 This creates a feed-forward mechanism, whereby the production of type I IFNs further increases the expression of molecules that drive IFN production in responding and neighboring cells. Although such feed-forward loops are highly adaptive in enabling the host to respond rapidly and broadly to viral infection, they also create the potential for amplifying immuno pathology in systemic auto immunity. Additionally, several antigens that are targeted in systemic autoimmune diseases are RevIews highly responsive to IFN, potentially augmenting antigen drive in these diseases (see below).
Induction of IFN expression
To initiate an effective anti-viral immune response all cells should be capable of sensing and responding appropriately to infection. In this regard, the host encodes a number of germ-line pattern recognition receptors (PRRs) that are expressed on immune and nonimmune cells. These receptors are capable of recognizing a wide array of conserved pathogen-associated molecular patterns (PAmPs) that do not occur under normal circumstances in the host. The PRRs sense specific viral and bacterial structures and induce the production of type I IFNs. Two types of PRR exist: ubiquitously expressed cytoplasmic nucleic acidsensing molecules and membrane-bound Toll-like receptors (TLRs). The expression of the latter is more limited than that of the cytoplasmic receptors (Table 2) .
Cytoplasmic nucleic-acid-sensing receptors
The retinoic-acid-inducible gene I (RIG-I)-like RNA helicases, which include RIG-I and melanoma differentiationassociated gene 5 (mDA5; also known as IFIH1), are a ubiquitously expressed group of cytoplasmic receptors that recognize and bind unique viral RNA structures and induce IFN-β production. [55] [56] [57] RIG-I is activated by 5' triphosphate single-stranded RNA (ssRNA) and short double-stranded RNA (dsRNA), 58 whereas mDA5 recognizes long dsRNA structures. 59 The presence of both forms of RNA is very unusual during normal host conditions. RIG-I and mDA5, therefore, respond to different viral species and provide coverage against a broad array of viruses. Accordingly, mice deficient in RIG-I or mDA5 are susceptible to distinct viral infections. [60] [61] [62] Binding of viral RNA enables interaction between the RIG-I-like he licases and downstream signaling molecules, which activate transcription factors and regulate the production of type I IFNs.
In addition, cytoplasmic sensors of DNA are important for the recognition of bacterial, and probably also viral, nucleic acid. 63 Studies have identified DNA-dependent activator of IFN-regulatory factors (DAI) as a receptor for bacterial DNA that induces type I IFN production. 64 The cytoplasmic nucleic-acid-sensing receptors enable cell-autonomous initiation of IFN production upon recognition of viral and bacterial nucleic acid. Although their expression is low in the steady state, these receptors are strikingly induced by type I IFNs, which enhances their capacity to recognize viral and bacterial nucleic acid and to propagate the antiviral response.
Recognition of nucleic acids by TlRs
TLRs are distinct from the cytoplasmic nucleic acid receptors in several ways, including the cells that express them, their subcellular localization, and the signal ing pathways that are activated by them. Nine TLRs have been identified in humans, of which three (TLR3, TRL7 and TLR9) recognize nucleic acid components and stimulate type I IFN production. Interestingly, TLR expression is also regulated by IFNs, further highlighting the amplifying principle of the IFN response. 53 TLR3 is triggered by dsRNA, whereas TLR7 recognizes guanosine-rich and uridine-rich ssRNA, and TLR9 senses unmethylated cytosine-phosphateguanine motifs. [65] [66] [67] [68] [69] TLR8 is also a receptor for ssRNA, but primarily elicits proinflammatory cytokine production. 70 TLR4, which is expressed on the cell surface, recognizes lipo polysaccharide, 71 and can stimulate type I IFN production. TLRs have been shown to mediate the recognition of viral structures in apoptotic debris and to initiate type I IFN production. In this regard, TLR7 recognizes nucleic acid from ssRNA viruses, whereas TLR9 facilitates the recognition of certain DNA viruses. 
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TLRs are primarily expressed on hematopoietic cells, but within this group their distribution varies widely by cell type. For instance, B cells and pDCs express TLR7 and TLR9, whereas myeloid DCs primarily express TLR3 and TLR8. [75] [76] [77] The subcellular restriction of TLRs to surface membranes and endosomes skews their sampling to extracellular material and is thought to prevent TLR signaling from within healthy hematopoietic cells. Clearly, however, self components derived from dying host cells and taken up by antigen-presenting cells could pose a challenge, particularly as some of the molecular patterns that are recognized by TLRs are also present in host nucleic acid (albeit at a lower density than is found in pathogen-derived nucleic acid).
Propagation of the IFN response
Numerous distinct signaling pathways are activated downstream of the nucleic-acid-sensing receptors, which converge at the activation of the IRF family of transcription factors, upstream of IFN production. 78 Four IRF family members (IRF1, IRF3, IRF5 and IRF7) are positive regulators of type I IFN production. These molecules regulate transcription at distinct type I IFN loci, thereby determining which type I IFN subtypes are expressed in the initiation and propagation of the IFN response.
79
IRF3 is constitutively expressed in the cytoplasm of cells, and when activated translocates to the nucleus to induce transcription primarily at the IFN-β locus. 80 IRF7, which is normally expressed at low levels in lymphoid cells but is induced by type I IFNs, is activated downstream of the same pathways that activate IRF3, and preferentially stimulates IFN-α gene transcription. 81 In the initiation phase of the IFN response, therefore, recognition of viral or bacterial PAmPs induces IRF3 activation and IFN-β production. IFN-β can induce the expression of IRF7, as well as the receptors and signal transduction molecules that activate IRF7, enabling a feed-forward loop whereby further recognition of PAmPs induces IFN-α gene transcription. 54, 82 pDCs have the unique capacity to rapidly secrete large quantities of type I IFNs upon recognition of nucleic acid structures by TLR7 or TLR9. [72] [73] [74] 83 These cells constitutively express high levels of IRF7, making them ideally suited to respond rapidly to PAmPs in the absence of prior IFN exposure. pDCs are, therefore, thought to have a central role in the self-amplifying nature of auto immune disease through the production of large quantities of type I IFNs, which mediate numerous downstream functional effects on target cells and cells of the immune system (see below). In addition, pDCs express IRF5, which induces transcription of IFN-α genes distinct from those induced by IRF7. 84, 85 As previously discussed, polymorphisms in the gene encoding IRF5 are associated with an increased risk of SLE, SS and SSc, [42] [43] [44] 46, 47 suggesting that IRF5 polymorphisms could affect IFN secretion by pDCs in response to TLR ligands. However, the functional significance and role of these polymorphisms in disease are not yet well understood.
The IRFs are critical regulators of the type I IFN response, controlling both the qualitative (that is, the subtypes expressed) and quantitative features of the response. Interestingly, IRF5 and IRF7 are both induced by type I IFNs, 54, 84 again reinforcing the self-amplifying capacity of this pathway. Inhibiting the feed-forward nature of IFN production, therefore, represents a potential therapeutic approach to systemic autoimmune diseases. moreover, selective inhibition of IRF5 or IRF7 could leave basal IFN-β production intact while limiting amplification of this pathway.
Downstream effects of IFN
Once produced, type I IFNs act in an autocrine and paracrine manner to trigger the heterodimeric type I IFN receptor (IFNAR), which is expressed on all nucleated cells. In molecular terms, binding of type I IFNs to the receptor complex induces dimerization of the IFNAR1 and IFNAR2 chains and the phosphorylation of associated Janus kinase family members TYK2 and JAK1. This enables activation of members of the STAT family, which autophosphorylate and homodimerize or hetero dimerize and translocate to the nucleus. There, they initiate transcrip tion of hundreds of IFN-stimulated genes, resulting in direct and indirect antiviral effects. 86 Further more, the activities of type I IFNs regulate the global immune response. 87 In physiological terms, type I IFNs regulate pathways in target cells, antigen-presenting cells (which direct the scope of the immune response) and effector cells (which mediate antiviral effects and tissue damage).
Induction of an antiviral state IFN-stimulated proteins mediate a variety of direct and indirect antiviral effects that are critical for inhibiting viral replication and enhancing clearance (Figure 1) . The IFN-regulated antiviral proteins of importance include members of the apolipoprotein B mRNA-editing enzyme catalytic polypeptide (APOBEC) family, which are packaged in nascent virions and mutate viral genomes, the mx GTPases, which associate with viral polymerases and inhibit viral gene transcription, and members of the tripartite motif family (including the autoantigen Ro/SSA 52 kD [Ro52, also known as TRIm21, or tripartite-motifcontaining 21]), which can inhibit viral replication at multiple stages in the life cycle. [88] [89] [90] Other molecules inhibit viral replica tion indirectly through broad effects on cellular processes. For example, RNA-activated protein kinase (PKR) inhibits viral protein synthesis by blocking cap-dependent messenger RNA translation. Furthermore, immune recognition is enhanced in cells exposed to type I IFNs. The induction of mHC class I expression results in enhanced presentation of viral and self antigens for recognition by the immune system, and is important for the effector phase of the immune response. Other changes include the induction of molecules (such as p53) 91 that increase susceptibility to cell-death-inducing stimuli, thus enhancing the killing of virally infected cells by the immune system.
Although it was initially believed that autoantigens targeted in systemic autoimmunity were ubiquitously expressed, it has now become clear that these molecules are expressed at significantly high levels in the target tissues RevIews of patients with systemic autoimmune disease. 2 Some of these molecules are expressed at low levels under normal circumstances, but are highly expressed upon exposure to IFNs. One such autoantigen is Ro52, which is broadly targeted in systemic auto immunity. 92 Once targeted by the immune system, enhanced Ro52 expression in cells responding to IFN signaling can increase the presentation of immunostimulatory Ro52 epitopes in the context of mHC class I molecules, facilitating their recognition by autoreactive T cells. Other autoantigens, although targeted in only a subset of the rheumatic diseases, are similarly regulated by type I IFNs, and their expression in the setting of elevated type I IFN levels might propagate the autoimmune response against them in specific phenotypes. For example, a member of the HIN-200 family, IFI16, is targeted in patients with SLE and SSc. 93, 94 By contrast, mDA5, which binds viral RNA and initiates type I IFN production, is frequently targeted in patients with dermatomyositis. 95 Defining the basis for the distinct phenotypic associations of antigens induced by type I IFNs is an important research priority.
maturation of antigen-presenting cells
The subtypes of type I IFN have the capacity to influence the generation of an adaptive immune response through their ability to activate and mature DCs. In the steady state, immature DCs maintain peripheral tolerance through the presentation of exogenously derived antigens in the absence of co-stimulation. when ac tivated, mature DCs are efficient stimulators of T-cell-dependent immune responses. Type I IFNs induce the expression of mHC class I and class II molecules, as well as costimulatory molecules, on DCs, which enables these cells to efficiently activate T cells. 96, 97 DC activation by type I IFNs also induces the expression of CC-chemokine receptor 7, which is necessary for homing to lymphoid organs, 98 where DCs interact with T cells and initiate an adaptive immune response. Longhi and colleagues 99 have shown that type I IFNs act directly on DCs to induce their maturation, and that IFNs are necessary for the efficient generation of CD4 T cell responses. Similarly, type I IFNs enhance CD8 T cell responses through activation of DCs. 100 In the setting of chronic IFN production, therefore, increased levels of immunostimulatory DCs 30 could challenge tolerance by continuously presenting self antigen in a proimmune context, potentially activating autoreactive cells that have survived negative selection in the thymus and periphery.
Activation of effector cells
In addition to their ability to influence the initiation of an adaptive immune response, type I IFNs have the capacity to enhance the survival and effector functions of cells that mediate immunopathology in systemic autoimmunity, thereby potentiating amplification. Type I IFNs have been shown to promote T-cell survival, 22, 101, 102 and to increase the cytolytic activity of NK cells and cytotoxic T cells (CTLs). 22, 103 Evidence directly implicates cytotoxic lymphocytes, which kill virally infected and transformed cells via the granzyme B (GrB) pathway, in the effector arm of tissue damage in systemic autoimmunity. Polarized CTLs surrounding myofibers that express mHC class I have been found in muscle biopsies from patients with polymyositis. 104 Similarly, effector lymphocytes expressing GrB are present at high levels in patients with SLE, and have been shown to correlate with disease activity. 105 many autoantigens are GrB substrates, RevIews and cleavage by GrB generates peptide fragments that are distinct from those generated by caspases during normal homeostatic cell death. 106 These novel fragments might not be tolerized during immune development, and could stimulate autoreactive T cells when presented by activated DCs. Enhanced effector functions of CTLs in response to type I IFNs could lead to increased tissue damage and augmented antigen load, thus propagating the autoimmune response.
Furthermore, type I IFNs have the ability to promote B-cell differentiation and antibody production.
107,108 many of the autoantigens that are frequently targeted in systemic autoimmune diseases are nucleic acid-protein complexes. In both human and murine systems, there is extensive evidence that signaling by nucleic-acid-containing immune complexes through TLRs induces IFN production. This finding suggests that the ability to ligate and activate TLRs might be a critical property of self antigens, constituting an additional element of the feed-forward loop. For example, autoantigen complexes that can co-ligate both B cell receptors and TLRs on B cells induce B cell activation and IFN secretion, further enhancing autoantibody production. 109, 110 In humans, co-ligation of Fc receptor and TLR9 by immune complexes in pDCs induces IFN secretion. 111 In mice, immune complexes that co-ligate Fc receptor and TLRs induce myeloid DC activation and IFN secretion. 112 In a murine model of lupus, TLR7 and TLR9 were shown to be critical for autoantibody production: TLR7-deficient animals had less-severe disease and failed to produce autoantibodies against ribonucleoprotein autoantigens, whereas TLR9-deficient animals did not produce anti-DNA antibodies. 113, 114 The ability of IFNs to enhance TLR expression, and the ability of TLR ligation by systemic autoimmune disease autoantigens to generate IFN secretion, creates a self-reinforcing cycle. The likelihood that additional components (for example, enhanced cytotoxicity pathways, increased sensitivity to cell death or increased autoantigen expression) contribute to this cycle is high. These additional components are included in the model of the potential activity of type I IFNs in systemic autoimmunity shown in Figure 2 .
Conclusions
The type I IFN response is a rapidly inducing, selfamplifying pathway that has the capacity to regulate both innate and adaptive immune responses. The feedforward nature of IFN production ensures that a vi gorous anti viral immune response is mounted. Although such feed-forward pathways are highly adaptive to rapid and effective virus eradication, these functions could be maladaptive in immune responses directed against host tissues. These self-amplifying loops are particularly hazardous if the ligands that drive the response are derived from self antigens contained within dying cells. Such reinforcing cycles should, however, be highly amenable to therapy.
Effectively impacting the type I IFN pathway and predict ing the side effects of treatment is dependent upon understanding the many reinforcing components of this system. Inhibitors of TLR signaling could prevent amplification of the IFN pathway by immune complexes. In this regard, it is relevant that hydroxychloroquine is used for the treatment of a variety autoimmune rheumatic diseases (such as SLE and RA), and has been shown to inhibit TLR signaling. 115, 116 Short-term use of IFN-α receptor inhibitors could be useful to break the selfamplifying cycle of tissue damage and IFN pro duction. In chronically treated individuals, however, selective inhibitors might prevent potentially catastrophic infections. Inhibitors of IRF5 or IRF7 could block the production of IFN-α, which is closely tied to disease activity and/or severity, and leave antiviral and/or antitumor effects of IFN-β unaltered. Neutralizing antibodies directed against IFN-α are being evaluated and could be highly effective at inhibiting the amplifying nature of the IFN response. Preliminary studies demonstrate that a single dose of IFN-α-neutralizing antibody decreases the expression of IFN-α-inducible genes in whole blood from patients with SLE, and that these effects persists for up to 12 weeks. 117 The IFN system might be therapeutically tractable in many other ways in systemic autoimmunity. Defining the key points of control and minimum basal function for safety in terms of antiviral and antitumor activities are essential areas for future research.
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